Overview

Aerosol Cyclosporine for Prevention of Lung Rejection

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy of aerosolized cyclosporine given in addition to the standard oral immunosuppressive drug regimen, in preventing acute rejection immediately after lung transplantation
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Azathioprine
Cyclosporine
Cyclosporins
Prednisone
Tacrolimus
Criteria
No eligibility criteria